Form 4: AnaptysBio CLO Sells Shares for Tax Obligations

AnaptysBio's Chief Legal Officer, Eric J. Loumeau, acquired shares through RSU settlement and subsequently sold a portion to cover tax withholding obligations.

Summary

• Eric J. Loumeau, Chief Legal Officer of AnaptysBio, Inc. (ANAB), reported transactions involving the company's common stock.
• On January 7, 2026, 5,888 shares of common stock were acquired through the settlement of restricted stock units (RSUs).
• Following this acquisition, Mr. Loumeau's direct beneficial ownership of common stock was 15,045 shares.
• On January 8, 2026, 2,210 shares of common stock were sold at a price of $44.71 per share.
• This sale was explicitly stated as a 'sell to cover' transaction to satisfy tax withholding obligations in connection with the RSU vesting and was not a discretionary transaction by the Reporting Person.
• After the sale, Mr. Loumeau's direct beneficial ownership of common stock was 12,835 shares.
• The RSUs vest as to 25% of the total annually, commencing on January 7, 2026, subject to Mr. Loumeau's continued provision of service to the Issuer on each vesting date.

Sentiment

Score: 5

Explanation: The filing details a routine, non-discretionary insider transaction related to equity compensation and tax obligations, providing no new material information about the company's operational or financial performance.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates continued employment and alignment of management's interests with shareholders through equity compensation.

Negatives

• A portion of shares were sold, which reduces the insider's direct ownership, although this was a non-discretionary sale for tax purposes.

Future Outlook

The filing indicates that the remaining Restricted Stock Units (RSUs) will continue to vest at a rate of 25% annually, commencing from January 7, 2026, contingent upon the Chief Legal Officer's continued service to the company.

Management Comments

• The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all industries for publicly traded companies when executives receive and vest equity compensation. It does not provide specific industry-wide insights.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction for tax purposes, not indicative of management's view on the stock's future value.
• Employees: The vesting of RSUs is a standard component of executive compensation, reinforcing retention and alignment.

Next Steps

• Remaining Restricted Stock Units (RSUs) will continue to vest annually at 25% commencing January 7, 2026, subject to continued service.

Key Dates

Recommendation

This Form 4 reports a standard 'sell to cover' transaction by an executive to satisfy tax obligations upon RSU vesting. It does not reflect a discretionary investment decision or provide new insights into the company's fundamental value or future prospects, thus not warranting a change in investment stance based solely on this filing.

Keywords

ANAPTYSBIO, ANAB, Form 4, insider transaction, RSU, stock sale, tax withholding, Eric J. Loumeau